SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant discussion following reports that Nvidia has paused evaluating its 18A chipmaking process, a crucial element of Intel's revitalized foundry strategy. However, much of the community is highly skeptical, calling the news old or manipulative, and arguing that 18A was primarily for internal use while future external foundry deals, potentially including Nvidia, are centered on the more advanced 14A node. Many investors express frustration over perceived short-term price suppression, yet maintain long-term confidence in Intel's competitive positioning.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is experiencing extreme volatility and intense investor focus as the market eagerly awaits an imminent FDA PDUFA decision for its life-saving drug, Narsoplimab, to treat TA-TMA. Following a trading halt for news pending, community sentiment is largely optimistic for approval, anticipating a significant price surge fueled by high short interest and the drug's first-in-class status for a condition with no existing treatment. The broader context of the recent de-risking deal with Novo Nordisk and previous regulatory hurdles fuels speculation of substantial long-term value and even a potential buyout, making this a pivotal moment for the company.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, which is touted as the largest commercial communications array ever deployed in low Earth orbit. This achievement is fueling significant bullish sentiment, with many anticipating the validation of its direct-to-device cellular broadband vision and rapid network expansion. However, discussions also reflect skepticism around the company's long-term profitability and current valuation, even as the community focuses on future scaling and execution milestones.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intensified speculation for a major partnership or buyout, catalyzed by a recent acquisition in the biotech sector and heightened discussions around its undervalued protein-based vaccine platform and combination influenza/COVID candidate. Shareholders are openly frustrated with management's perceived inaction and lack of communication, echoing an activist investor's push for a strategic review to unlock value from Novavax's differentiated non-mRNA technology, especially as concerns about mRNA vaccine safety grow. This confluence of factors, coupled with high short interest, positions the company for potentially significant market movement should a transformative deal be announced.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is a major talking point as Sanofi announced its acquisition for $15.50 per share, valuing the company at $2.2 billion and representing a substantial premium. This move integrates Dynavax's marketed adult Hepatitis B vaccine, its shingles candidate, and a recently licensed oral COVID-19 vaccine program into Sanofi's global immunization portfolio. While many long-term shareholders are relieved to see a resolution, a significant portion of the community feels the acquisition price undervalues the company's assets and growth prospects.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the market assesses its recently completed Marigold acquisition and updated strong guidance for future financial performance. Community discussions highlight optimism for its advanced AI platform and proprietary data in the evolving marketing sector, with many anticipating significant upside following its participation in an upcoming key industry event. Despite some short-term price fluctuations, investors are closely watching for its potential re-rating as an an undervalued AI-driven marketing powerhouse.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following the FDA's expanded approval of AQVESME (mitapivat) for adults with alpha- or beta-thalassemia, establishing it as the first and only oral treatment for this condition. The community is actively discussing the commercial implications and the drug's high cost, while also reflecting on broader concerns about management's communication style and historical execution.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing significant positive momentum, driven by its upcoming inclusion in the S&P MidCap 400 index, effective early next year. The community views this as a major catalyst for structural demand, anticipating increased institutional buying, enhanced liquidity, and greater visibility for the Agentic AI and automation leader.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust is surging to new all-time highs, driven by intensifying industrial demand from rapidly expanding sectors like AI data centers, EVs, and solar, alongside significant global supply concerns. The rally is further fueled by China's impending export restrictions on silver, with market participants eagerly discussing a potential 'silver squeeze' and a fundamental re-evaluation of its value, though some anticipate a near-term correction after its rapid ascent.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is heavily trending amid widespread speculation of an imminent buyout, fueled by recent significant insider purchases and strong financial fundamentals including growing Lupkynis sales and a robust cash position. The community is actively discussing the potential Phase 2 indications for AUR200, while many shareholders voice frustration over perceived management opacity and repeatedly call for a change in leadership to unlock further value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InspireMD (NYSE:NSPR) Shares Up 2% - Should You Buy?

InspireMD (NYSE:NSPR) Trading 2% Higher - Here's Why...

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of 0.00% and +31.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates

Hologic (HOLX) delivered earnings and revenue surprises of +2.73% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +20.60% and +3.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

Shares of InspireMD, Inc. (NSPR) dipped nearly 1% on Friday morning after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.inspiremd.com/en/press-center/inspiremd-reports-first-quarter-2025-financial-results/">reported</a> a wider-than-expected first quarter (Q1) loss.The company’s revenue for the quarter increased 1.2% year-on-year (YoY) to $1.52 million, above an analyst estimate of $1.45 billion, as per Finchat data.The marginal increase in revenue was driven by the continued adoption of the company’s CGuard technology in existing markets. It was offset by the impact of foreign exchange and distributors managing inventory levels in anticipation of an approval for CGuard Prime in Europe.InspireMD’s CGuard Prime carotid stent system is used to treat carotid artery disease and prevent stroke.Net loss per share came in at $0.22, compared to a net loss of $0.21 per share for the same period in 2024, but wider than an estimated loss of $0.2.The company said that it is continuing to engage with the U.S. Food and Drug Administration (FDA) regarding the application it submitted to obtain marketing approval for the CGuard Prime carotid stent system.The company also expressed optimism about approval for the system in the third quarter of 2025.CEO Marvin Slosman said that the firm’s commercial team is ready to execute at scale upon receiving FDA approval for the technology.“We continue to work interactively with the FDA and are optimistic for an anticipated approval of CGuard Prime in the third quarter of 2025. Despite dynamics within the agency and the timing of our audit in February, we are confident the remaining items will be successfully completed,” he said.On Stocktwits, retail sentiment around InspireMD stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:629/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_11_03_25_AM_png_e35692eebb.webp" alt="NSPR's Sentiment Meter and Message Volume as of 11 a.m. ET on May 9, 2025 | Source: Stocktwits" width="629" height="62"><figcaption>NSPR's Sentiment Meter and Message Volume as of 11 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NSPR">NSPR stock</a> is down by about 3% this year but up by nearly 17% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ocugen-reports-lower-than-expected-q1-loss/chiWHRQRblX">Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa (Photo by Silas Stein/picture alliance via Getty Images)

InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic

The company’s revenue increased marginally to $1.52 million, driven by the continued adoption of its CGuard technology in existing markets.

Equity

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.20	--	--	N/A
Q3 '25	-$0.19	-$0.17	12.82%	BEAT
Q2 '25	-$0.26	-$0.26	--	EXPECTED
Q1 '25	-$0.20	-$0.22	-10.00%	MISSED
Q4 '24	-$0.19	-$0.19	2.56%	BEAT

NSPR
InspireMD Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NSPR News

NSPRInspireMD Inc